$19.07▾ 4.41%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Beta Bionics, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days28 articles
1 bullish0 neutral27 bearish
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX
ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX
BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC